Pixabay/Michal Jarmoluk
21 October 2020
MeiraGTx and Janssen Pharmaceuticals have reported improvements in retinal sensitivity among patients who received gene therapy for x-linked retinitis pigmentosa (XLRP).
Results from the study at nine months were presented at the Euretina 2020 Virtual Congress (2 – 4 October).
The investigational gene therapy, AAV-RPGR, resulted in “sustained improvements” in retinal sensitivity at nine-months, as well as reducing the time taken by study participants to walk around a vision-guided mobility maze.
Moorfields Eye Hospital consultant ophthalmologist and trial investigator, Michel Michaelides, shared that the gene therapy improved the ability of study participants to navigate in low light conditions.
“These exciting results continue to suggest that AAV-RPGR has the potential to be a much-needed and important treatment option for those living with XLRP,” he said.
Researchers found that six out of the seven patients involved in the trial demonstrated improvement or stability in retinal sensitivity in the treated eye.
Results from the study at nine months were presented at the Euretina 2020 Virtual Congress (2 – 4 October).
The investigational gene therapy, AAV-RPGR, resulted in “sustained improvements” in retinal sensitivity at nine-months, as well as reducing the time taken by study participants to walk around a vision-guided mobility maze.
Moorfields Eye Hospital consultant ophthalmologist and trial investigator, Michel Michaelides, shared that the gene therapy improved the ability of study participants to navigate in low light conditions.
“These exciting results continue to suggest that AAV-RPGR has the potential to be a much-needed and important treatment option for those living with XLRP,” he said.
Researchers found that six out of the seven patients involved in the trial demonstrated improvement or stability in retinal sensitivity in the treated eye.
Comments (0)
You must be logged in to join the discussion. Log in